DNAVision purchases 4 of Life Technologies' NGS platforms

Jan 13 2011

DNAVision, one of European leading genetic analysis service providers, is pleased to announce the purchase of four next-generation sequencing platforms from Life Technologies, including two latest 5500xl SOLiD™ Systems.

“The broad range of end-to-end automated RNA and DNA applications, with market leading accuracy make it the perfect choice for service providers and core laboratories, either as a stand-alone system or alongside other sequencing technologies.”

Life Technologies' latest sequencing systems are installed in our Brussels South facility and implemented in the highest quality certifications environment (GMP, GLP, CLIA, CAP, ISO17025).

This latest acquisition will further strengthen DNAVision's current portfolio of next- generation sequencing services beside the two Illumina Hiseq 2000 and Roche 454.

Initially, DNAVision will use the 5500xl SOLiD System for whole human genome sequencing projects for its pharmaceutical and medical research customers.

"With this latest acquisition which completes our actual next gen sequencing platforms, we are pleased to announce that we are now the number one private service provider in Europe in term of capacity of DNA sequencing. We are ready to answer to the big demand of whole human genome sequencing in 2011 and to offer a whole human genome sequencing service at a very competitive price, close to current exome sequencing price. We forecast that in 2011, our whole genome sequencing service at a price of 7500€ will replace a large part of exome research projects. In the future, as we are the only company in the world to be ISO17025 accredited, CLIA certified, CAP accredited, GLP certified and GMP certified, we will be able to produce human genome data with any quality certification requested, being the first company to provide human genome sequencing data deemed suitable for medical research purposes and to move with this breakthrough technology to support personalized medicine" says Jean-Pol Detiffe, CEO of DNAVision.

"The 5500xl provides flexibility to efficiently process small and large numbers of samples," said Andy Watson, Vice President Product Management for SOLiD. "The broad range of end-to-end automated RNA and DNA applications, with market leading accuracy make it the perfect choice for service providers and core laboratories, either as a stand-alone system or alongside other sequencing technologies."